Recent clinical trials targeting Nrf2 in renal diseases have demonstrated outstanding beneficial effects improving renal function in patients with diabetes and CKD stage 3, an effect unseen with any other therapeutic approaches. The gene discussed is NFE2L2; the disease is diabetes mellitus.